Varanasi News Magazine

Creative Biolabs Launches Brand-new Protease Inhibitor Drug Development Service for SARS-CoV-2 Treatment

 Breaking News
  • No posts were found

Creative Biolabs Launches Brand-new Protease Inhibitor Drug Development Service for SARS-CoV-2 Treatment

March 02
01:07 2021
As a world-leading service provider in the field of coronavirus, Creative Biolabs, with world-class equipment, facilities and highly dedicated formulation specialists, now introduces development services of inhibitors of host cell protease for the potential prophylactics and therapeutics to prevent or treat the SARS-CoV-2 infection.

New York, USA – March 1, 2021 – Currently, there are COVID-19 vaccines having been approved by the U.S. Food and Drug Administration (FDA) and even more in clinical trials. However, given that the situation of COVID-19 infection remains severe, the research and development of COVID-19 drugs is still urgent. Recently, the FDA issued guidance for medical product developers covering vaccines, diagnostics and therapeutics products to address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes COVID-19.

As a top-class institution as well as experienced supplier in biotech markets, Creative Biolabs has been focusing on SARS-CoV-2 vaccine discovery (SARS-CoV-2 MVA Vectored Vaccine, in silico vaccine, mRNA vaccine, etc ) and drug discovery services to the utmost of its power, and now unveils brand-new antiviral drug development services on inhibitors of host cell protease, covering Lopinavir/Ritonavir and Darunavir.

For example, as a highly potent protease inhibitor for the HIV-1 protease, lopinavir and/or ritonavir have been reported to be effective in the treatment of severe acute respiratory syndrome (SARS). Thus their potential to be SARS-CoV-2 inhibitors is expected since the sequence and structural conservation of lopinavir/ritonavir bind site between these two coronaviruses have been evaluated 96% identical.

Creative Biolabs now offers investigational lopinavir/ritonavir and darunavir inhibitor development services to facilitate clients’ research and drug discovery process by a multitude of related services:

* The catalytic mechanism, the structure, and dynamic behaviors study and antiviral activity assays
* In vitro/in vivo pharmacodynamics studies
* In vitro ADME
* In vivo PK studies
* Prophylactic in vivo efficacy studies
* Pharmacology studies and various animal models
* Toxicity study and safety evaluation for preclinical trial
* Pre-formulation and formulation development, dose prediction and drug abuse tests

Other inhibitor development services at Creative Biolabs involve nucleoside analogue inhibitors (such as Ribavirin, Mizoribine, Acyclovir Fleximer, BCX4430 for SARS-CoV-2 treatment), viral protease inhibitors, RNA synthesis inhibitors, neuraminidase inhibitors, Abl kinase inhibitors, etc.

More information about coronavirus-related vaccine and drug discovery services, IVD immunoassays as well as a wide range of products can be found on https://sars-cov-2.creative-biolabs.com.

About Creative Biolabs

Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com